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cluded drug acquisition, supply and labour costs (in 1998
Canadian dollars). RESULTS: Two days of IV therapy
cost $57.48, $78.51 and $82.52, for azithromycin, eryth-
romycin, and cefuroxime, respectively. The total cost of a
10-day course of therapy was $136.36 for azithromycin
and $165.58 for cefuroxime  erythromycin ($126.36
for cefuroxime alone and $208.07 for cefuroxime 
erythromycin). Approximately 280 CAP patients were
seen at our institution in 1996, translating into potential
cost savings of $8,182 per year with azithromycin. CON-
CLUSION: Azithromycin IV/PO is a cost-effective alter-
native for in-patient treatment of CAP.
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OBJECTIVE: This study outlines the management strat-
egy used to treat ribavirin-induced hemolytic anemia
(RIHA) when used in combination therapy in the treat-
ment of chronic hepatitis C (CHC). It also estimates the
direct cost of treating RIHA per treatment course.
METHODS: A systematic review of the literature (1991–
1999) was conducted to abstract information on the fre-
quency and management of RIHA in the treatment of
CHC. Costs were obtained from a large private health in-
surance database from the state of Washington, and from
Drug Topics Red Book. Decision analytic techniques
were used to develop a model (base case) that estimated
the cost of RIHA. Additionally, several one-way sensitiv-
ity analyses, best and worst cases, and two additional
clinical scenarios were simulated with the model. RE-
SULTS: RIHA occurs in approximately 8% of those
treated for CHC. Standard of care dictates management
by dosage reduction or discontinuation of the ribavirin
component of therapy. The decrease in effectiveness of
therapy, as a result of this reduction/discontinuation, has
not been studied. We estimate the direct cost of treating
RIHA at $170 per patient per 48-week treatment course.
The cost ranges from $68 to $692 in the best and worst
case scenarios, respectively. CONCLUSIONS: RIHA is
an anticipated side effect of therapy for CHC. Manage-
ment of RIHA is simple and effective, however its impact
on overall treatment effectiveness is not known. The di-
rect cost of treating RIHA is low, although the likely de-
crease in effectiveness may increase indirect costs over
time, and deserves further study.
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Pneumonia was the third leading admitting diagnosis at a
large tertiary care hospital costing $12,653 per admis-
sion. The American Thoracic Society recommends the
use of a -lactam with or without macrolide as the pre-
ferred antimicrobial regimen for patients with CAP ad-
mitted to a non-ICU. OBJECTIVE: The objective of this
evaluation was to compare ceftriaxone alone (regimen 1)
versus ceftriaxone plus macrolide (regimen 2) using
length of stay, antibiotic costs, and total hospital charges
from a hospital perspective. METHODS: The data were
collected prospectively during December 1998 and May
1999. Fine et al 1998 defined risk scores for CAP and
classified them into 5 categories: 1 (low risk) through 5
(high risk). Most of our patient population belonged to
risk class 2. We compared 26 patients diagnosed with
CAP and stratified into risk class 2. Thirteen patients re-
ceived regimen 1 and 13 patients received regimen 2. RE-
SULTS: We found statistically significant differences in
hospital length of stay, antibiotic costs, and total hospital
charges. Patients who received ceftriaxone alone had
shorter lengths of stay (2.7  1.9 days vs. 5.6  3.9 days,
P  0.028), lower antibiotic costs ($93.02  $58.79 vs.
$169.11  $108.81, P  0.036), and lower total hospi-
tal charges per patient ($2,362.41  $1,442.18 vs.
$4,431.42  $3,108.92, P  0.040) than patients who
received ceftriaxone plus macrolide. CONCLUSION:
Ceftriaxone alone may be sufficient in the treatment of
hospitalized CAP patients who are classified in risk class 2.
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The seven-valent pneumococcal conjugate vaccine (PCV)
is the only vaccine to immunize children under two years
old against Streptococcus Pneumoniae, a leading cause of
meningitis, bacteremia, pneumonia, otitis media, and si-
nusitis. OBJECTIVE: The purpose of this analysis is to
assess the cost-effectiveness of PCV in Canada, the
United Kingdom, France, Germany, Italy, and Spain.
METHODS: A Markov cohort simulation model was
constructed to compare the health and economic out-
comes of children vaccinated with PCV versus unvacci-
nated. Estimated disease-specific incidence and mortality
